Clinical Trials Information System (CTIS) bitesize talk: Part I-only applications and Part II requirements in CTIS, Online, 15:30 - 17:00 Amsterdam time (CEST), from 30/08/2023 to 30/08/2023

Opinion/decision on a Paediatric investigation plan (PIP): Trilaciclib (dihydrochloride), decision type: , therapeutic area: , PIP number: P/0451/2022

Opinion/decision on a Paediatric investigation plan (PIP): Bimervax,SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer – B.1.351-B.1.1.7 strains, decision type: , therapeutic area: , PIP number: P/0465/2022

Opinion/decision on a Paediatric investigation plan (PIP): Beremagene geperpavec, decision type: , therapeutic area: , PIP number: P/0464/2022

Opinion/decision on a Paediatric investigation plan (PIP): Ianalumab, decision type: , therapeutic area: , PIP number: P/0450/2022

Opinion/decision on a Paediatric investigation plan (PIP): branaplam, decision type: , therapeutic area: , PIP number: P/0449/2022

Opinion/decision on a Paediatric investigation plan (PIP): Enspryng,satralizumab, decision type: , therapeutic area: , PIP number: P/0448/2022

Opinion/decision on a Paediatric investigation plan (PIP): Entyvio,vedolizumab, decision type: , therapeutic area: , PIP number: P/0382/2023

Opinion/decision on a Paediatric investigation plan (PIP): Freeze-dried allergen extract of Betula pendula pollen, decision type: , therapeutic area: , PIP number: P/0463/2022

Opinion/decision on a Paediatric investigation plan (PIP): Glucagon analogue linked to a human immunoglobulin Fc fragment, decision type: , therapeutic area: , PIP number: P/0468/2022